This breast cancer cell line model system together with clinical data from the patients allowed us to resolve the effect of nuclear and cytoplasmic maspin in breast cancer on proliferation and its potential as a genetic drug in breast cancer gene therapy. This evidence concerns the gene SERPINB5 and breast carcinoma.